Table 1 Clinical characteristics of patients with renal biopsy after liver transplantation

Demography

Age, years; median(min-max)

55(31–75)

Gender distribution, male/female

13/1

Interval between liver transplantation and kidney biopsy, years; median(min-max)

35.7(2.80-134.73)

Etiology of liver disease prior liver transplantation

HBV, n(%)

12(85.7%)

Schistosomiasis, n(%)

1(7.1%)

Primary sclerosing cholangitis, n(%)

1(7.1%)

Comorbidity

hypertension, n(%)

10(71.4%)

diabetes, n(%)

5(35.7%)

hepatocellular carcinoma, n(%)

8(57.1%)

Immunosuppression protocol at the time of renal biopsy

CNI/MMF

5(35.7%)

CNI/mTOR inhibitor

4(28.6%)

CNI/MMF/prednisone

1(7.1%)

CNI

2(14.3%)

mTOR inhibitor/MMF

1(7.1%)

mTOR inhibitor

1(7.1%)

Biochemistry at the time of liver transplantation

Scr, umol/L; median(min-max)

75.0(41.6, 129.3)

eGFR-EPI, mL/min/1.73m²;median(min-max)

103.9(55.2, 177.8)

Biochemistry at the time of renal biopsy

Scr, umol/L; median(min-max)

118.5(86.0, 232.0)

BUN, mmol/L; median(min-max)

8.10(4.80, 14.40)

eGFR-EPI, mL/min/1.73m²;median(min-max)

48.5(26.0, 81.0)

Proteinuria(g/24 h), median(min-max)

3128.7(126.4,11183.7)

UACR(mg/g),median(min-max)

2318.1(25.60,4868.50)

Urine ɑ1-microglobulin(mg/L),median(min-max)

28.9(0.00, 51.70)

Urine β2-microglobulin(mg/L),median(min-max)

1.80(0.00, 15.30)

Serum albumin(g/L),median(min-max)

32.6(26.6, 46.1)

Uric acid(umol/L),median(min-max)

417.5(296.0, 667.2)

ALT(U/L),median(min-max)

13.0(3.0, 28.0)

AST(U/L),median(min-max)

17.0(10.0, 37.0)

TB(umol/L),median(min-max)

7.95(2.70, 45.80)

INR,median(min-max)

0.91(0.75, 1.08)

aPTT(s),median(min-max)

28.0(11.0, 30.7)

PLT(10^9/L),median(min-max)

132.0(79.0, 245.0)

HBA1c(%),median(min-max)

5.2(4.5, 6.8)

Abnormal Immunological indicators

C3/C4 decreased

2(14.3%)

IgA/IgM/IgG increased

2(14.3%)

ANA positive

2(14.3%)

RF positive

1(7.1%)